StockWatch
·
Medical Specialities
Quarterly ResultAug 4, 2026, 06:17 AM

Henry Schein Q2 Non-GAAP EPS $1.27, Sales $3.5B; Raises FY2026 Guidance

AI Summary

Henry Schein, Inc. reported strong financial results for the second quarter ended June 27, 2026, with non-GAAP diluted EPS increasing to $1.27 and total net sales growing 6.7% to $3.5 billion. The company also raised its full-year 2026 guidance for non-GAAP diluted EPS, total sales growth, and Adjusted EBITDA growth, citing sustained momentum and solid operational execution. Additionally, Henry Schein repurchased $200 million of common stock during the quarter.

Key Highlights

  • Q2 2026 non-GAAP diluted EPS was $1.27, up from $1.10 in Q2 2025.
  • Q2 2026 total net sales reached $3.5 billion, a 6.7% increase year-over-year.
  • Q2 2026 Adjusted EBITDA was $288 million, compared to $256 million in Q2 2025.
  • Raised FY2026 non-GAAP diluted EPS guidance to $5.29-$5.39 from $5.23-$5.37.
  • Increased FY2026 total sales growth guidance to 4.5%-5.5% from 3%-5%.
  • Repurchased approximately 2.6 million shares for $200 million in Q2 2026.
  • Remaining share repurchase authorization stands at $455 million.